Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations.

Abuse-deterrent formulations (ADFs) of pharmaceutical opioids have limited capacity to reduce extra-medical use and harm; their impact is likely restricted to prevention of specific practices among population sub-groups. This debate highlights the importance of viewing ADFs as one component in a range of public health responses. Greater involvement of invested parties (e.g., prescribers, consumers) and reframing terminology will reduce discrimination and stigma.

[1]  M. Jauncey.  What are our aims, and why? , 2018, Addiction.

[2]  Lewis S. Nelson.  Are abuse-deterrent opioid formulations all they are crushed up to be? , 2018, Addiction.

[3]  K. Humphreys.  Evaluating dynamic impacts of abuse-deterrent prescription opioid formulations. , 2018, Addiction.

[4]  R. Bruno,et al.  Post‐marketing studies of pharmaceutical opioid abuse‐deterrent formulations: a framework for research design and reporting , 2018, Addiction.

[5]  R. Bluthenthal,et al.  Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. , 2018, The International journal on drug policy.

[6]  E. Wood,et al.  Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada. , 2018, The New England journal of medicine.

[7]  T. Dobbins,et al.  The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. , 2018, The lancet. Psychiatry.

[8]  Nabarun Dasgupta,et al.  Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. , 2018, American journal of public health.

[9]  K. Seear,et al.  The productive techniques and constitutive effects of 'evidence-based policy' and 'consumer participation' discourses in health policy processes. , 2017, Social science & medicine.

[10]  K. Vowles,et al.  Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.

[11]  A. Winstock,et al.  Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. , 2011, Drug and alcohol review.

[12]  Abuse-Deterrent Opioids — Evaluation and Labeling Guidance for Industry , 2015 .